LYEL - Multiplikator P/S Lyell Immunopharma Inc

Tandha merek Lyell Pharma (LYEL)

The recruitment of leading immunologists and generous research investments are driving growth for Lyell Immunopharma (LYEL). Strict bioethical oversight and an eco-friendly approach to waste management strengthen the company's foundation, while innovations in solid tumor treatment accelerate data releases. The company's price/sales multiple reflects phases of asset consolidation, while 35947.70 determines the latest fundamental valuation metric.

LYEL (Lyell Immunopharma Inc) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 17.11.2026

Lyell Immunopharma Inc (LYEL) - rincian metrik lan laporan keuangan

Analisis umum perusahaan:Lyell Immunopharma, Inc., LYEL
Produk asil prodhuksi Lyell

Institutional capital assesses the attractiveness of Lyell Immunopharma (LYEL) through the lens of market value relative to generated revenue, which is critical for companies with extreme R&D expenditures and no commercial product. By analyzing the P/S multiple trend, investors compare market capitalization with revenue to identify asset overheating and evaluate the risks to business continuity given the dependence on external financing.

Perusahaan pesaing

Kapitalisasi marang pendapatan ImmunityBio Corp IBRX|Immunocore Holdings - Kapitalisasi marang pendapatan|Multiplikator P/S Janux Corp JANX|RCUS - Rasio rega marang pendapatan|ZYME (zymeworks.com) - Rasio kapitalisasi marang pendapatan|Tango Therapeutics Corp (TNGX) - Rasio rega marang pendapatan|Rega marang dodolan Iovance (IOVA)|Kapitalisasi marang pendapatan IMTX|XNCR - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan CMPX (Compass Bio)|Kapitalisasi marang volume dodolan REPL|Multiplikator P/S IPHA (Innate Pharma)|Rasio kapitalisasi pasar marang pendapatan PYXS|Compugen Limited - Multiplikator P/S|Rega marang dodolan IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Rasio rega marang pendapatan|MiNK Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|HOWL (Werewolf) - Multiplikator P/S|Multiplikator P/S immixbio.com|Rasio rega marang pendapatan ALX Oncology Holdings (ALXO)|CUE - Rega marang dodolan|PDS Biotechnology Corporation - Kapitalisasi marang pendapatan|Sonnet BioTherapeutics (SONN) - Rega marang dodolan|MAIA - Rasio rega marang pendapatan|LIMN: Rasio rega marang pendapatan|LVTX: Multiplikator P/S|Rega marang dodolan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Multiplikator P/S|INTS (Intensity Therapeutics) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan gritstonebio.com GRTS|Rasio kapitalisasi pasar marang pendapatan KA|NEXI - Rasio rega marang pendapatan|Turnstone Biologics Corp. - Kapitalisasi marang volume dodolan|VCNX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan HARP